Reversible Inhibitors of Monoamine Antidepressants Market

RIMAs are used as antidepressants. They work by reducing the activity of monoamine oxidase which is a chemical found throughout the body. Monoamine oxidase breaks down noradrenaline (also called norepinephrine) and serotonin and other chemicals made and used by the body and brain. These chemicals are important in emotions and depression.

Reversible Inhibitors of Monoamine Antidepressants Market contains market size and forecasts of Reversible Inhibitors of Monoamine (RIMA) Antidepressants in Global, including the following market information:

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Nonselective MAO-Ainhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Reversible Inhibitors of Monoamine (RIMA) Antidepressants include Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly& Co., GlaxoSmithKline Plc, H. Lundbeck, Merck, Pfizer and Teva Pharmaceutical Industries Ltd. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Reversible Inhibitors of Monoamine (RIMA) Antidepressants companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, by Type, 2021 (%)

Nonselective MAO-Ainhibitors

Selective MAO-B inhibitors

Nonselective MAO-B inhibitors

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, by Application, 2021 (%)

Depression Treatment

Parkinson's Disease Treatment

Other Therapy

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Reversible Inhibitors of Monoamine (RIMA) Antidepressants revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Reversible Inhibitors of Monoamine (RIMA) Antidepressants revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Alkermes Plc

Allergan Plc

Bristol Myers Squibb Co.

Eli Lilly& Co.

GlaxoSmithKline Plc

H. Lundbeck

Merck

Pfizer

Teva Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.